32507349

$333,825,413

Brand : Background: Bipolar disorder (BD) is a chronic and disabling psychiatric disorder. The treatment of BD still remains a significant clinical challenge due to the complex nature of the disease. Nutraceutical therapy as adjunctive role is a promising therapy for BD. Sulforaphane (SFN), a broccoli extract, was reported to be effective for emotional problems and cognitive impairment. However, clinical research of SFN in the treatment of BD was rare. Therefore, this study is designed to evaluate the adjuvant role of SFN in the treatment of BD. Methods: This is a randomized, double-blinded, placebo-controlled, parallel-group clinical trial. A total of 100 patients who meet inclusion criteria will be assigned to receive quetiapine plus SFN or quetiapine plus placebo in a 1:1 ratio. The total duration of the study will be 12 weeks including 5 follow ups. The primary outcome is in the Montgomery-Asberg depression rating scale. The secondary outcomes are the quick inventory of depressive symptomatology-self report, Hamilton anxiety rating scale, young mania rating scale, cognitive function, inflammatory factors, and intestinal flora. Any adverse events will be recorded throughout the trial. Discussion: This trial will provide evidences to evaluate the efficacy and safety of SFN combined with quetiapine in the treatment of BD patients, as well as the adjuvant role of SFN in combination. Trial registration: This study protocol was registered at the Chinese clinical trial registry (ChiCTR2000028706).
Catalogue Number : 2930900000
Specification : Congchong Wu 1, Xingyang Chen 2, Jianbo Lai 1 3 4, Yi Xu 1 3 4, Shaohua Hu 1 3 4
CAS number : The efficacy and safety of sulforaphane as an adjuvant in the treatment of bipolar depressive disorder: Study protocol for a randomized, double-blinded, placebo-controlled, parallel-group clinical trial
Formula : CS(=O)CCCCN=C=S
Molecular Weight : 32590809
PUBCHEM ID : Meili Wang 1, Die Pu 2, Yuxing Zhao 1, Jinliang Chen 1, Shiyu Zhu 1, Ankang Lu 2, Zhilin Liao 1, Yue Sun 1, Qian Xiao 3
Volume : inchi=1s/c6h11nos2/c1-10(8)5-3-2-4-7-6-9/h2-5h2,1h3

In stock

Description

Catalogue Number

2930900000

Analysis Method

Specification

Congchong Wu 1, Xingyang Chen 2, Jianbo Lai 1 3 4, Yi Xu 1 3 4, Shaohua Hu 1 3 4

Storage

Inhibitory effects of phytochemicals on NLRP3 inflammasome activation: A review

Molecular Weight

32590809

Appearance

Melis Olcum 1, Bora Tastan 2, Ilkcan Ercan 2, Irem B Eltutan 2, Sermin Genc 3

Botanical Source

32445760

Structure Type

Aims: Skeletal muscle diseases have become to be the most common complication in patients with type 2 diabetic mellitus (T2DM). However, the effective therapies against skeletal muscle diseases are not yet available. Sulforaphane (SFN) is an organic isothiocyanate found in cruciferous plants. Our aim was to explore whether SFN could attenuate the skeletal muscle diseases in spontaneous type 2 diabetic db/db mice. Materials and methods: The db/m and littermate db/db mice were treated with SFN or dimethyl sulfoxide. The grip strength of mice was measured by a grasping forcing machine. The electron transmission microscopy was used to perform the skeletal muscle. The western blot was used to detect the nuclear factor E2-related factor 2/heme oxygenase 1 (Nrf2/HO-1) signal pathway related proteins, and inflammatory and apoptotic associated proteins. The mRNA levels of anti-inflammatory and anti-oxidative relative genes were detected by RT-QPCR. Key findings: We found that SFN could significantly increase the grip strength of the db/db mice. The lean mass and gastrocnemius mass were increased in the db/db mice after administration with SFN. Additionally, the db/db mice restored the skeletal muscle fiber organization after SFN treatment. Mechanistically, SFN could activate the Nrf2/HO-1 signal pathway, and downregulate the expression of inflammatory and apoptotic associated proteins. Furthermore, SFN could also regulate the mRNA levels of anti-inflammatory and anti-oxidative related genes. Significance: Our results demonstrated that SFN can protect against skeletal muscle diseases in db/db type 2 diabetic mice and provide a potential drug to prevent skeletal muscle dysfunction in T2DM patients.

Description :

Sulforaphane protects against skeletal muscle dysfunction in spontaneous type 2 diabetic db/db mice